O	0	9	Technical
O	10	17	effects
O	18	20	of
O	21	27	adding
B-intervention	28	29	1
I-intervention	30	31	%
I-intervention	32	41	lidocaine
I-intervention	42	44	to
I-intervention	45	55	technetium
I-intervention	56	62	sulfur
I-intervention	63	70	colloid
O	71	74	for
O	75	83	sentinel
O	84	93	lymphatic
O	94	101	mapping
O	102	104	in
O	105	110	early
O	111	117	breast
O	118	124	cancer
O	124	125	:
O	126	134	analysis
O	135	137	of
O	138	142	data
O	143	147	from
O	148	149	a
O	150	156	double
O	156	157	-
O	157	162	blind
O	163	173	randomized
O	174	184	controlled
O	185	190	trial
O	190	191	.

O	192	193	A
O	194	202	practice
O	203	211	standard
O	212	214	in
O	215	223	sentinel
O	224	229	lymph
O	230	234	node
O	235	236	(
O	236	239	SLN
O	239	240	)
O	241	248	mapping
O	249	251	in
O	252	258	breast
O	259	265	cancer
O	266	268	is
O	269	280	intradermal
O	281	290	injection
O	291	293	of
O	294	304	technetium
O	304	305	-
O	305	308	99m
O	309	315	sulfur
O	316	323	colloid
O	324	325	(
O	325	327	Tc
O	327	328	-
O	328	331	99m
O	331	332	)
O	332	333	,
O	334	343	resulting
O	344	346	in
O	347	358	significant
O	359	366	patient
O	367	377	discomfort
O	378	381	and
O	382	386	pain
O	386	387	.

O	388	389	A
O	390	398	previous
O	399	409	randomized
O	410	420	controlled
O	421	426	trial
O	427	433	showed
O	434	438	that
O	439	445	adding
O	446	455	lidocaine
O	456	458	to
O	459	461	Tc
O	461	462	-
O	462	465	99m
O	466	479	significantly
O	480	487	reduced
O	488	500	radioisotope
O	501	510	injection
O	510	511	-
O	511	518	related
O	519	523	pain
O	523	524	.

O	525	527	We
O	528	534	tested
O	535	542	whether
O	543	544	1
O	545	546	%
O	547	556	lidocaine
O	557	564	admixed
O	565	569	with
O	570	572	Tc
O	572	573	-
O	573	576	99m
O	577	584	affects
O	585	596	feasibility
O	597	599	of
O	600	603	SLN
O	604	611	mapping
O	611	612	.

O	613	620	Between
O	621	628	January
O	629	633	2006
O	634	637	and
O	638	643	April
O	644	648	2009
O	648	649	,
B-total-participants	650	653	140
B-eligibility	654	662	patients
I-eligibility	663	667	with
I-eligibility	668	673	early
I-eligibility	674	680	breast
I-eligibility	681	687	cancer
O	688	692	were
O	693	701	randomly
O	702	710	assigned
O	711	712	(
O	712	713	1
O	713	714	:
O	714	715	1
O	715	716	:
O	716	717	1
O	717	718	:
O	718	719	1
O	719	720	)
O	721	723	to
O	724	731	receive
O	732	740	standard
O	741	748	topical
O	749	750	4
O	751	752	%
O	753	762	lidocaine
O	763	768	cream
O	769	772	and
O	773	784	intradermal
O	785	787	Tc
O	787	788	-
O	788	791	99m
O	792	793	(
B-control	793	800	control
O	800	801	)
O	802	804	or
O	805	807	to
O	808	811	one
O	812	814	of
O	815	820	three
O	821	826	other
O	827	832	study
O	833	839	groups
O	839	840	:
B-control	841	848	topical
I-control	849	856	placebo
I-control	857	862	cream
O	863	866	and
O	867	876	injection
O	877	879	of
O	880	882	Tc
O	882	883	-
O	883	886	99m
O	887	897	containing
O	898	904	sodium
O	905	916	bicarbonate
O	917	918	(
O	918	924	NaHCO3
O	924	925	)
O	925	926	,
O	927	928	1
O	929	930	%
O	931	940	lidocaine
O	940	941	,
O	942	944	or
O	945	949	both
O	949	950	.

O	951	954	All
O	955	958	SLN
O	959	963	data
O	964	968	were
O	969	978	collected
O	979	992	prospectively
O	992	993	.

O	994	999	Study
O	1000	1006	groups
O	1007	1011	were
O	1012	1022	comparable
O	1023	1026	for
O	1027	1046	clinicopathological
O	1047	1057	parameters
O	1057	1058	.

O	1059	1061	As
O	1062	1072	previously
O	1073	1081	reported
O	1081	1082	,
O	1083	1086	the
O	1087	1095	addition
O	1096	1098	of
O	1099	1100	1
O	1101	1102	%
O	1103	1112	lidocaine
O	1113	1115	to
O	1116	1119	the
O	1120	1132	radioisotope
O	1133	1141	solution
O	1142	1155	significantly
O	1156	1164	improved
B-outcome	1165	1172	patient
I-outcome	1173	1180	comfort
O	1180	1181	.

B-outcome	1182	1189	Overall
I-outcome	1190	1193	SLN
I-outcome	1194	1208	identification
I-outcome	1209	1213	rate
O	1214	1216	in
O	1217	1220	the
O	1221	1226	trial
O	1227	1230	was
O	1231	1233	93
O	1234	1235	%
O	1235	1236	.

B-outcome	1237	1246	Technical
I-outcome	1247	1254	aspects
I-outcome	1255	1257	of
I-outcome	1258	1261	SLN
I-outcome	1262	1268	biopsy
O	1269	1273	were
O	1274	1281	similar
O	1282	1285	for
O	1286	1289	all
O	1290	1296	groups
O	1296	1297	,
O	1298	1307	including
B-outcome	1308	1312	time
I-outcome	1313	1317	from
I-outcome	1318	1327	injection
I-outcome	1328	1330	to
I-outcome	1331	1340	operation
O	1340	1341	,
B-outcome	1342	1347	first
I-outcome	1348	1351	SLN
I-outcome	1352	1353	(
I-outcome	1353	1356	SLN
I-outcome	1357	1358	1
I-outcome	1358	1359	)
O	1360	1365	gamma
O	1366	1371	probe
O	1372	1378	counts
O	1378	1379	,
B-outcome	1380	1382	ex
I-outcome	1383	1387	vivo
I-outcome	1388	1394	counts
O	1395	1398	for
O	1399	1402	SLN
O	1403	1404	1
O	1405	1408	and
O	1409	1412	SLN
O	1413	1414	2
O	1414	1415	,
O	1416	1419	and
B-outcome	1420	1428	axillary
I-outcome	1429	1432	bed
I-outcome	1433	1439	counts
O	1439	1440	.

B-outcome	1441	1444	SLN
I-outcome	1445	1459	identification
I-outcome	1460	1465	rates
O	1466	1470	were
O	1471	1481	comparable
O	1482	1495	statistically
O	1495	1496	:
O	1497	1504	control
O	1505	1506	(
B-cv-bin-percent	1506	1508	96
I-cv-bin-percent	1509	1510	%
O	1510	1511	)
O	1511	1512	,
O	1513	1522	lidocaine
O	1523	1524	(
B-iv-bin-percent	1524	1526	90
I-iv-bin-percent	1527	1528	%
O	1528	1529	)
O	1529	1530	,
O	1531	1537	sodium
O	1538	1549	bicarbonate
O	1550	1551	(
B-iv-bin-percent	1551	1553	97
I-iv-bin-percent	1554	1555	%
O	1555	1556	)
O	1556	1557	,
O	1558	1561	and
O	1562	1568	sodium
O	1569	1580	bicarbonate
O	1580	1581	-
O	1581	1590	lidocaine
O	1591	1592	(
B-iv-bin-percent	1592	1594	90
I-iv-bin-percent	1595	1596	%
O	1596	1597	)
O	1597	1598	.

O	1599	1602	The
O	1603	1610	control
O	1611	1616	group
O	1617	1620	had
O	1621	1622	a
O	1623	1636	significantly
O	1637	1643	higher
B-outcome	1644	1647	SLN
I-outcome	1648	1649	2
I-outcome	1649	1650	/
I-outcome	1650	1653	SLN
I-outcome	1654	1655	1
I-outcome	1656	1658	ex
I-outcome	1659	1663	vivo
I-outcome	1664	1669	count
I-outcome	1670	1675	ratio
O	1675	1676	,
O	1677	1680	and
O	1681	1684	the
B-outcome	1685	1691	number
I-outcome	1692	1694	of
I-outcome	1695	1699	SLNs
I-outcome	1700	1708	detected
O	1709	1712	was
O	1713	1726	significantly
O	1727	1734	reduced
O	1735	1737	in
O	1738	1741	the
O	1742	1751	lidocaine
O	1752	1758	versus
O	1759	1761	no
O	1761	1762	-
O	1762	1771	lidocaine
O	1772	1778	groups
O	1779	1780	(
O	1780	1781	p
O	1782	1783	<
O	1784	1785	0
O	1785	1786	.
O	1786	1788	05
O	1788	1789	)
O	1789	1790	.

O	1791	1799	Addition
O	1800	1802	of
O	1803	1804	1
O	1805	1806	%
O	1807	1816	lidocaine
O	1817	1819	to
O	1820	1828	standard
O	1829	1841	radioisotope
O	1842	1850	solution
O	1851	1854	for
O	1855	1858	SLN
O	1859	1866	mapping
O	1867	1869	in
O	1870	1876	breast
O	1877	1883	cancer
O	1884	1886	is
O	1887	1897	associated
O	1898	1902	with
O	1903	1908	fewer
O	1909	1913	SLNs
O	1914	1922	detected
O	1922	1923	,
O	1924	1927	but
O	1928	1930	it
O	1931	1935	does
O	1936	1939	not
O	1940	1946	appear
O	1947	1949	to
O	1950	1960	compromise
O	1961	1964	SLN
O	1965	1979	identification
O	1979	1980	.
